Pam3CSK4-Get quote

Description

Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1].—COVID-19-immunoregulation–C81H156N10O13S—Antiviral Res. 2022 May 21;203:105346.|Biochem Biophys Res Commun. 2024 Feb 15, 149661.|Emerg Microbes Infect. 2023 Oct 30:105244.|Int Immunopharmacol. 2022 Feb 15;106:108613.|Mol Immunol. 2021 Feb;130:85-95.|Sci Rep. 2023 Nov 9;13(1):19440.|Int Immunopharmacol. December 2022, 109312.|Sci Rep. 2022 Oct 12;12(1):17058.-[1]Irvine KL, et al. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet Res. 2013 Jul 4;44:50.|[2]Du X, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One. 2011 May 6;6(5):e19583.|[3]Chen Y, et al. TLR2 agonist Pam3CSK4 enhances the antibacterial functions of GM-CSF induced neutrophils to methicillin-resistant <i>Staphylococcus aureus</i>. Microb Pathog. 2019 May;130:204-212.–112208-00-1–1510.23—-CCCCCCCCCCCCCCCC(OCC(OC(CCCCCCCCCCCCCCC)=O)CSC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O–Infection; Inflammation/Immunology–H2O–Toll-like Receptor (TLR)–TLR1;TLR2–Immunology/Inflammation–Peptides